Cargando…
Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
The binding mode of aromatic sulphonamides and clinically licenced drugs to the three carbonic anhydrase (CA, EC 4.2.1.1) isoforms from the human pathogen V. cholerae was here thouroghly characterised by a joint docking and molecular dynamics in silico protocol. In fact, VchCA, VchCAβ, and VchCAγ ar...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822066/ https://www.ncbi.nlm.nih.gov/pubmed/33472446 http://dx.doi.org/10.1080/14756366.2020.1862102 |
_version_ | 1783639554194931712 |
---|---|
author | Bonardi, Alessandro Nocentini, Alessio Osman, Sameh Mohamed Alasmary, Fatmah Ali Almutairi, Tahani Mazyad Abdullah, Dalal Saied Gratteri, Paola Supuran, Claudiu T. |
author_facet | Bonardi, Alessandro Nocentini, Alessio Osman, Sameh Mohamed Alasmary, Fatmah Ali Almutairi, Tahani Mazyad Abdullah, Dalal Saied Gratteri, Paola Supuran, Claudiu T. |
author_sort | Bonardi, Alessandro |
collection | PubMed |
description | The binding mode of aromatic sulphonamides and clinically licenced drugs to the three carbonic anhydrase (CA, EC 4.2.1.1) isoforms from the human pathogen V. cholerae was here thouroghly characterised by a joint docking and molecular dynamics in silico protocol. In fact, VchCA, VchCAβ, and VchCAγ are crucial in the pathogen life cycle and growth and represent innovative targets to fight V. cholerae proliferation overcoming the spreading chemoresistance to the available drugs. A set of 40 sulphonamides/sulfamates VchCAs inhibitors was studied using the proteins homology built 3 D models unveiling the key and stable interactions responsible for a potent CA inhibition. This study has the aim to offer insights and guidelines for the future rational design of potent and selective inhibitors targeting CA isoforms from V. cholerae or other human pathogens. |
format | Online Article Text |
id | pubmed-7822066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-78220662021-01-29 Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study Bonardi, Alessandro Nocentini, Alessio Osman, Sameh Mohamed Alasmary, Fatmah Ali Almutairi, Tahani Mazyad Abdullah, Dalal Saied Gratteri, Paola Supuran, Claudiu T. J Enzyme Inhib Med Chem Research Paper The binding mode of aromatic sulphonamides and clinically licenced drugs to the three carbonic anhydrase (CA, EC 4.2.1.1) isoforms from the human pathogen V. cholerae was here thouroghly characterised by a joint docking and molecular dynamics in silico protocol. In fact, VchCA, VchCAβ, and VchCAγ are crucial in the pathogen life cycle and growth and represent innovative targets to fight V. cholerae proliferation overcoming the spreading chemoresistance to the available drugs. A set of 40 sulphonamides/sulfamates VchCAs inhibitors was studied using the proteins homology built 3 D models unveiling the key and stable interactions responsible for a potent CA inhibition. This study has the aim to offer insights and guidelines for the future rational design of potent and selective inhibitors targeting CA isoforms from V. cholerae or other human pathogens. Taylor & Francis 2021-01-20 /pmc/articles/PMC7822066/ /pubmed/33472446 http://dx.doi.org/10.1080/14756366.2020.1862102 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Bonardi, Alessandro Nocentini, Alessio Osman, Sameh Mohamed Alasmary, Fatmah Ali Almutairi, Tahani Mazyad Abdullah, Dalal Saied Gratteri, Paola Supuran, Claudiu T. Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study |
title | Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study |
title_full | Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study |
title_fullStr | Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study |
title_full_unstemmed | Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study |
title_short | Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study |
title_sort | inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822066/ https://www.ncbi.nlm.nih.gov/pubmed/33472446 http://dx.doi.org/10.1080/14756366.2020.1862102 |
work_keys_str_mv | AT bonardialessandro inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy AT nocentinialessio inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy AT osmansamehmohamed inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy AT alasmaryfatmahali inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy AT almutairitahanimazyad inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy AT abdullahdalalsaied inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy AT gratteripaola inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy AT supuranclaudiut inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy |